[C-peptide residual secretion makes difference on type 1 diabetes management?].

about

Implicações clínicas da persistência de anti-GAD positivo e peptídeo C detectável em pacientes com diabetes melito tipo 1 de longa duração

P2860

Q57831167-3CA85B85-31C7-420B-AE99-EB1337EA9AB4

P2860

[C-peptide residual secretion makes difference on type 1 diabetes management?].

Item

http://www.wikidata.org/entity/Q46625419

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

[C-peptide residual secretion makes difference on type 1 diabetes management?].

@en

[C-peptide residual secretion makes difference on type 1 diabetes management?].

@nl

type

Item

label

[C-peptide residual secretion makes difference on type 1 diabetes management?].

@en

[C-peptide residual secretion makes difference on type 1 diabetes management?].

@nl

prefLabel

[C-peptide residual secretion makes difference on type 1 diabetes management?].

@en

[C-peptide residual secretion makes difference on type 1 diabetes management?].

@nl

P1476

[C-peptide residual secretion makes difference on type 1 diabetes management?].

@en

P2093

Adolpho Milech

http://www.w3.org/2001/XMLSchema#string

José Egídio Paulo de Oliveira

http://www.w3.org/2001/XMLSchema#string

Melanie Rodacki

http://www.w3.org/2001/XMLSchema#string

P2860

Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus

Stabilisation of diabetic retinopathy following simultaneous pancreas and kidney transplant.

Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus.

Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus.

Type I diabetes mellitus. A chronic autoimmune disease.

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.

Does partial preservation of residual beta-cell function justify immune intervention in recent onset Type I diabetes?

Prevention of vascular and neural dysfunction in diabetic rats by C-peptide.

The role of nitric oxide in the development of diabetic angiopathy.

Molecular and cellular effects of C-peptide--new perspectives on an old peptide.

P304

322-333

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1590/S0004-27302008000200020

http://www.w3.org/2001/XMLSchema#string

P407

Amanung Portuges

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18438543

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

[C-peptide residual secretion makes difference on type 1 diabetes management?].

about

P2860

P2860

[C-peptide residual secretion makes difference on type 1 diabetes management?].

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921